Mode
Text Size
Log in / Sign up
N/A Completed N=1,410 Randomized Triple-blind Supportive Care

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

Source: ClinicalTrials.gov NCT04514458 ↗
Enrolled (actual)
1,410
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy — 176; 117 Participants

Summary

A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single health system.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy
176; 117 —
SECONDARY
Percentage of Patients on Beta Blockers
606; 521 —
SECONDARY
Percentage of Patients on ACE Inhibitors
83; 92 —
SECONDARY
Percentage of Patients on ARBs
111; 85 —
SECONDARY
Percentage of Patients on ARNIs
334; 285 —
SECONDARY
Percentage of Patients on MRAs
232; 203 —
SECONDARY
Percentage of Patients on SGLT2 Inhibitors
144; 103 —
SECONDARY
Rate of One-year All-cause Mortality
75; 68 —
SECONDARY
Rate of 30-day Hospital Admission
47; 63 —
SECONDARY
Rate of 30-day All-cause Emergency Department Visits
86; 77 —
SECONDARY
Total Six-month Healthcare Costs
— —
SECONDARY
Percentage of Filled Prescriptions
— —
SECONDARY
Medication Dose of Any Prescribed Beta Blocker
— —
SECONDARY
Medication Dose of Any Prescribed ACEi
— —
SECONDARY
Medication Dose of Any Prescribed ARB
— —
SECONDARY
Medication Dose of Any Prescribed ARNI
— —
SECONDARY
Medication Dose of Any Prescribed MRA
— —
SECONDARY
Medication Dose of Any Prescribed SGLT2 Inhibitor
— —

Eligibility Criteria

Patient Inclusion Criteria:

  • Age 18 or over
  • Seen in eligible internal medicine or cardiology clinic
  • Left ventricular ejection fraction less than or equal to 40%
  • Registered in the Yale Heart Failure Registry

Patient Exclusion Criteria:

  • Opted out of EHR-based research
  • Under hospice care
  • Already receiving each targeted class of evidence-based HFrEF medical therapy

Selection of Providers:

  • Practicing at an eligible internal medicine or cardiology clinic
  • High frequency of visits by eligible patients based on retrospective chart review
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04514458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search